Method and medicine for treating Huntington's disease
AssigneeTalengen International Limited
InventorJinan Li
Life of this patent
Estimating the term…
Abstract
Provided are a method and drug for treating Huntington's disease, which includes: administering a therapeutically effective amount of a component of a plasminogen activation pathway or a related compound thereof to a subject. Also provided are a drug, pharmaceutical composition, product, and kit used for treating Huntington's disease and containing the above component or compound.
Claims15
A method for treating Huntington's disease, comprising administering a therapeutically effective amount of plasminogen to a subject with Huntington's disease, wherein the plasminogen is the only active ingredient for said treatment, wherein treating Huntington's disease comprises alleviating one or more of a) a movement disorders, b) cognitive impairment, or c) a neuropsychiatric symptom that is associated with Huntington's disease, wherein the movement disorder associated with Huntington's disease comprises a voluntary movement disorder or an involuntary movement disorder wherein the plasminogen comprises an amino acid sequence as set forth in SEQ ID NO:
- 2, 6, 8, 10, 12, or 14.
A method for treating Huntington's disease, comprising administering a therapeutically effective amount of plasminogen to a subject with Huntington's disease, wherein the plasminogen is used in combination with one or more other drugs or treatment methods, wherein the other drugs or treatment methods are selected from one or more of:
- anti-dopaminergic drugs, dopamine receptor inhibitors, antipsychotic drugs, γ-aminobutyrate transaminase inhibitors, cell transplantation therapy, and gene therapy, wherein treating Huntington's disease comprises alleviating one or more of a) a movement disorders, b) cognitive impairment, or c) a neuropsychiatric symptom that is associated with Huntington's disease, wherein the movement disorder associated with Huntington's disease comprises a voluntary movement disorder or an involuntary movement disorder wherein the plasminogen comprises an amino acid sequence as set forth in SEQ ID NO:
- 2, 6, 8, 10, 12, or 14.
Dependencies are inferred from the claim text.